Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

Summary

To determine the efficacy and tolerability of deferasirox in the treatment of Porphyria Cutanea Tarda. Primary objective - the elimination of all blistering within 6 months of treatment. Secondary objective - decrease in total body iron levels.

Timeline

Start

2008-01

Primary completion

2010-04

Completion

2010-04

Publications

• Pandya AG, Nezafati KA, Ashe-Randolph M, Yalamanchili R. Deferasirox for porphyria cutanea tarda: a pilot study. Arch Dermatol. 2012 Aug;148(8):898-901. doi: 10.1001/archdermatol.2012.807.

Drugs

Indications